Alligator Bioscience AB (publ) Interim report January-June 2019
Competitive safety data for ADC-1013. Significant events April-June• Janssen presented data from the clinical Phase I study with ADC-1013 in ...
Alligator Bioscience submits clinical trial application for ATOR-1017
Lund, Sweden, June 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...
Frontier – A Magazine about Alligator Bioscience and Immuno-oncology
Two Alligator projects presented at ASCO. "The American Society of Clinical Oncology (ASCO) is a professional organization for oncologis ...
Frontier – A Magazine about Alligator Bioscience and Immuno-oncology
Two Alligator projects presented at ASCO. "The American Society of Clinical Oncology (ASCO) is a professional organization for oncologis ...
Alligator Bioscience to present the ATOR-1015 Phase I study outline at ASCO
Lund, Sweden, May 16, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the outline of the ongoing Phase I study w ...
Alligator Bioscience: ADC-1013 clinical Phase I data to be presented at ASCO
Lund, Sweden, May 15, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will prese ...
Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on May 9, 2019
Lund, Sweden, May 9, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutical ...
The Nomination Committee’s proposal for the annual shareholders’ meeting in Alligator Bioscience AB (publ)
Lund, Sweden, April 17, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the Nomination Committee in Alligator Bi ...
Alligator Bioscience AB (publ) Interim report January-March 2019
First patient dosed in Phase I clinical study of ATOR-1015 Significant events January-March• First patient dosed in Phase I clinical study o ...